Pharmaceutical giant Pfizer to combine with Mylan

Pharmaceutical giant Pfizer to combine with Mylan

Pfizer is buying Mylan in an all-stock deal and combining the $10bn generic pharmaceutical company with its own off-patent branded and generic business.

The Pfizer business, called Upjohn, makes Lipitor, Celebrex and Viagra.

Mylan, based just outside of Pittsburgh, is best known for its EpiPen, an injector used to halt life-threatening allergic reactions.

Pfizer shareholders will own 57% of the combined new company and Mylan shareholders will own 43%.

The deal today arrives at a precarious time for big drugmakers who are threatened by patent protection losses and lower-priced rivals.

The new company will be incorporated in Delaware, US and run operations in Pittsburgh, Shanghai and Hyderabad, India.

The combination is expected to close in the middle of next year.

- Associated Press

More in this Section

Protesters climb onto North Sea oil platformsProtesters climb onto North Sea oil platforms

German exports to UK drop again in first seven months of 2019German exports to UK drop again in first seven months of 2019

Businesses on both sides of Irish border ‘already affected by Brexit’Businesses on both sides of Irish border ‘already affected by Brexit’

US Economists back spending moreUS Economists back spending more


Lifestyle

Helen O’Callaghan says we are the least strict in all of Europe.Praise over punishment: Irish parents least strict in Europe - study

Kya deLongchamps detects a hint of rebellion behind the ritual of afternoon tea.Vintage View: English tradition of afternoon tea won't exit with Brexit

Friends and Young Offenders actors Shane Casey and Dominic MacHale speak to Pat Fitzpatrick about struggling to make it but why they are not seeking out fame.‘I was down to a euro’ - The Young Offenders actors tell of struggle to make it in acting

Gerry Fitzgerald runs Bandon Books Plus in Riverview Shopping Centre, Bandon, Co Cork.We Sell Books: Turning over a new leaf from bank to bookshop in Bandon

More From The Irish Examiner